ClinicalTrials.gg
RecruitingNCT05342792Updated Apr 25, 2022

Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma

A Phase 3 interventional study of PD-1 antibody and Capecitabine in Nasopharyngeal Carcinoma, sponsored by Sun Yat-sen University. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-04-25.

Sponsored by Sun Yat-sen University · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2022; still recruiting 4 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
556
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 140 studies testing Immune checkpoint inhibitors in Nasopharyngeal Carcinoma — 73 open to participants now, 98 under way, 27 of them phase 3. A drug class: Immune checkpoint inhibitors · Nasopharyngeal Carcinoma.

Planned enrollment
6th of 140
556 · median 75
Started
2022
with 25 others
Phase 3
26 of 140
18 open now
Primary completion
2027-06
later than 60 of 97 live
Registered
70th of 140
by date
Lead sponsor
44 of 140
Sun Yat-sen University

Among the 140 studies testing Immune checkpoint inhibitors in Nasopharyngeal Carcinoma, this one is the 6th largest by planned enrollment, is one of 26 that started in 2022, is one of 26 in phase 3, reaches primary completion later than 60 of the 97 other live ones, and was the 70th registered.

Nasopharyngeal Carcinoma

683 studies on the registry are indexed under Nasopharyngeal Carcinoma; 270 are open to participants now.

Browse Nasopharyngeal Carcinoma studies →

Open to participants now

73 of the 140 studies testing Immune checkpoint inhibitors in Nasopharyngeal Carcinoma are open now, in 9 countries. Recruiting first, the newest first:

68 more — sign in →

By country, each count listing its studies:

All 73 open studies →

About Immune checkpoint inhibitors

A class of medicines: which ones, and the studies of each, are on its page →

Who these studies take

Of the 186 Nasopharyngeal Carcinoma studies recruiting now, 42 (23%) set no upper age limit and 135 (73%) stop at 75 or younger; 9 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 140 studies testing Immune checkpoint inhibitors in Nasopharyngeal Carcinoma, or all of them as a file.
02

Study summary

This trial is aimed to investigate whether additional adjuvant PD-1 antibody treatment could improve survival in high-risk nasopharyngeal carcinoma compared to metronomic capecitabine alone.

Read the detailed description

In this multicenter, randomised controlled, phase 3 trial, patients with T4N+/TanyN2-3 (AJCC/UICC 8th system), or non-metastatic nasopharyngeal carcinoma with pretreatment EBV DNA > 4000 copies/ml, will be randomized in a 1:1 ratio to receive metronomic capecitabine with or without PD-1 antibody every 3 weeks for 1 year after curative chemoradiation.

03

Conditions studied

  • Nasopharyngeal Carcinoma

Keywords

  • PD-1 antibody
  • Metronomic capecitabine
  • Adjuvant therapy
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age at diagnosis: 18 \~ 65 years old;
  2. confirmed primary nasopharyngeal carcinoma with "non-keratinizing carcinoma (WHO criteria)";
  3. Locoregionally advanced nasopharyngeal carcinoma (T4N + or TanyN2-3M0, or TanyNanyM0 pretreatment EBVDNA ≥ 4000 copies/mL) was diagnosed according to the American Joint Committee on Cancer/Union for International Cancer Control (AJCC/UICC) 8th edition clinical staging system.
  4. Induction and concurrent chemoradiotherapy with the recommended regimen have been completed;
  5. score: 0 \~ 1 points (Appendix II);
  6. It is recommended to initiate therapy within 1 month after the completion of the last radiotherapy treatment, no later than 6 weeks;
  7. Normal bone marrow function: white blood cell count > 4 × 109/L, concentration > 90 g/L, count > 100 × 109/L;
  8. Normal liver and kidney function: total ≤ 1.5 times the ; and/or alanine aminotransferase ≤ 2.5 times the upper limit of normal; alkaline phosphatase ≤ 2.5 times the upper limit of normal; ≥ 60 mL/min;
  9. Subjects must sign the form, and must be willing and able to comply with the visits, treatment regimen, laboratory tests and other requirements specified in the study protocol;
  10. Female subjects of and male subjects with partners of childbearing potential must agree to use reliable (e.g., condoms, regular contraceptives as directed) from screening through 1 year after treatment.

Exclusion criteria

Exclusion Criteria:

  1. Positive surface antigen and hepatitis B virus quantification > 1 × 1000 copies/ml, or positive anti- virus antibody;
  2. Positive anti- antibody or diagnosis of acquired immunodeficiency syndrome (i.e., AIDS);
  3. Conditions such as dysphagia, chronic diarrhea, or bowel obstruction that would interfere with oral medication.
  4. Patients with severe chronic or active infection that must be treated with systemic antibacterial, antifungal or antiviral therapy before randomization, including but not limited to tuberculosis infection
  5. Active, known or suspected disease (including but not limited to uveitis, enteritis, hepatitis, pituitary disease, nephritis, vasculitis, hyperthyroidism, hypothyroidism, and asthma requiring bronchiectasis). Except for type I diabetes, hypothyroidism requiring hormone replacement therapy and skin diseases not requiring systemic treatment (such as vitiligo, psoriasis or alopecia); clinicians should perform necessary history, examination and examination before enrollment for the above diseases and then exclude them;
  6. Interstitial lung disease or pneumonia requiring oral or intravenous therapy within 1 year;
  7. Definite clinical evidence of persistent local disease or distant after chemoradiotherapy;
  8. Systemic hormonal or other therapy with an equivalent dose of > 10 mg prednisone/day within 28 days prior to . Subjects with systemic sex hormone doses ≤ 10 mg prednisone/day or inhaled/topical corticosteroids may be included.
  9. Uncontrolled heart disease, such as: 1) heart failure, level ≥ 2; 2) unstable angina; 3) history of myocardial infarction in the past year; 4) supraventricular arrhythmia or ventricular arrhythmia requiring treatment or intervention;
  10. Pregnant or lactating women (pregnancy test should be considered for sexually active women of childbearing age);
  11. Previous or current other other than adequately treated non-melanoma skin cancer, carcinoma in situ of the cervix, and papillary thyroid carcinoma;
  12. Receipt of within 30 days prior to the first course of tislelizumab;
  13. History of organ transplantation;
  14. Other conditions that may jeopardize patient safety or compliance as assessed by the investigator, such as serious illness (including psychiatric disorders) requiring prompt treatment, severely abnormal test results, and other family or social risk factors.
  15. Patients who received surgical treatment, biological therapy, or immunotherapy during or before radiotherapy;
  16. Patients who are receiving or are likely to receive other chemotherapy, biological therapy, or immunotherapy History of severe to other monoclonal antibodies;
  17. Chemotherapy or surgery (except diagnostic) of the primary tumor or lymph nodes before standard treatment.
  18. History of radiation therapy prior to standard therapy (except for non-melanoma skin cancer).
  19. Patients who are known to be intolerable or sensitive to any therapeutic agents.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
556 participants (estimated)

Study arms

  • Experimental
    Metronomic Capecitabine with PD-1 antibody arm

    Patients randomised to this arm will receive metronomic capecitabine (650mg/m2, BID, PO) and Tislelizuamb (200mg, iv drip, Q3W) for 1 year as adjuvant therapy, beginning 4-6 weeks after chemoradiation.

    Drug: PD-1 antibody · Drug: Capecitabine

  • Active comparator
    Metronomic Capecitabine alone arm

    Patients randomised to this arm will receive metronomic capecitabine (650mg/m2, BID, PO) alone for 1 year as adjuvant therapy, beginning 4-6 weeks after chemoradiation.

    Drug: Capecitabine

Interventions

  • DrugImmune checkpoint inhibitorsStudies of Immune checkpoint inhibitorsImmune checkpoint inhibitors pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Tislelizumab:200 mg per dose, intravenous infusion over 30 minutes, every 3 weeks as a cycle for 17 cycles after concurrent chemoradiotherapy

    Also known as: Tislelizumab

  • Capecitabine : 650 mg/m2 bid, orally, d1-21, every 3 weeks as a cycle for 17 cycles after concurrent chemoradiotherapy

06

What researchers measure

Primary outcomes

  1. failure-free survival

    calculated from the date of randomisation to the date of locoregional failure, distant failure, or death from any cause, whichever occurred first

    Time frame: 3 years

Secondary outcomes

  1. overall survival

    calculated from date of randomisation to death

    Time frame: 5 years

  2. distant metastasis-free survival

    calculated from date of randomisation to the first distant failure

    Time frame: 3 years

  3. locoregional recurrence-free survival

    locoregional recurrence-free survival

    Time frame: 3 years

  4. adverse events (AEs) and severe adverse events (SAE)

    graded according to NCI CTCAE v5.0

    Time frame: 5 years

  5. quality of life (QoL)

    the change of QoL from randomization to 12 months after chemoradiation, graded according to EORTC QLQ-C30 V3.0

    Time frame: 3 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Complete de-identified patient data set

Supporting information: Study protocol, Statistical analysis plan

Time frame: Beginning 9 months and ending 24 months following article publication

Access criteria: Proposals should be emailed to the PI to gain access

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2022 (actual). Primary completion is estimated for Jun 2027, 62 months after the start.

Of 84 phase 3 interventional studies under Nasopharyngeal Carcinoma, half reached primary completion within 69 months of starting (the median), counting those still running; a quarter within 51 and three quarters within 82. This study's planned 62 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2022
First posted
Apr 25, 2022
StartActual
Apr 17, 2022
Primary completionEst.
Jun 2027
CompletionEst.
Jun 2029
Last update
Apr 25, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 25, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05342792
Collaborators
Tongji Hospital, Wuhan Union Hospital, China, Xiangya Hospital of Central South University, Affiliated Cancer Hospital of Guizhou Medical University, Cancer Hospital of Guangxi Medical University, First People's Hospital of Foshan, Chongqing University Cancer Hospital, Hubei Cancer Hospital, Hunan Cancer Hospital, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Fifth Affiliated Hospital, Sun Yat-Sen University, Shandong Provincial Hospital
Responsible party
Jun Ma, MD (Hospital Deputy Dean, Sun Yat-sen University) — Principal investigator
First posted
Apr 25, 2022
Start date
Apr 17, 2022
Primary completion
Jun 2027 (estimated)
Completion
Jun 2029 (estimated)
Last update
Apr 25, 2022

Study contacts

Jun Ma, MD
Contact
majun2@mail.sysu.edu.cn
+862087343469
Yuan Zhang, PhD
Contact
zhangyuan@sysucc.org.cn
+862087343469
Jun Ma, MD
principal investigator · Sun Yet-senU

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Immune checkpoint inhibitors

Start the discussion